Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro

Chinese Medical Journal

Volumn 125, Issue 24, 2012, Pages 4338-4343

  Shao, Cui Jie ^a   Wu, Ming Wei ^a   Chen, Fu Rong ^a   Li, Cong ^a   Xia, Yun Fei ^a   Chen, Zhong Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

2 propylpentanoic acid; Cell line; Glioma; Radiosensitivity

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; TEMOZOLOMIDE; VALPROIC ACID;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; FLOW CYTOMETRY; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; RADIOSENSITIVITY; STUDENT T TEST;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; FLOW CYTOMETRY; GLIOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; VALPROIC ACID;

EID: 84874335994     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.24.004     Document Type: Article

References (24)

1. Bahl A, Sharma DN, Kumar M, Basu KS, Rath GK. Radiation-induced malignant gliomas: is there a role for reirradiation? In regard to Paulino et al. Int J Radiat Oncol Biol Phys 2008; 72: 304-305.
2. Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin 2007; 25: 1141-1171. (Pubitemid 47610812)
3. Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 126-128.
4. Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res 2011; 67: 175-195.
5. Jia Q, Li Y, Xu D, Li Z, Zhang Z, Zhang Y, et al. Radiosensitivity of glioma to Gamma Knife treatment enhanced in vitro and in vivo by RNA interfering Ku70 that is mediated by a recombinant adenovirus. J Neurosurg 2010; 113:228-235.
6. Dehmel F, Ciossek T, Maier T, Weinbrenner S, Schmidt B, Zoche M, et al. Trithiocarbonates: exploration of a new head group for HDAC inhibitors. Bioorg Med Chem Lett 2007; 17: 4746-4752. (Pubitemid 47187711)
7. Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res 2011; 67: 175-195.
8. Balakrishnan L, Milavetz B. HDAC inhibitors stimulate viral transcription by multiple mechanisms. Virol J 2008; 5: 43.
9. Chen X, Wong P, Radany E, Wong JY. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 2009; 24: 689-699.
10. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer ceils in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009; 8: 2221-2231.
11. Gotfryd K, Skladchikova G, Lepekhin EA, Berezin V, Bock E, Walmod PS. Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erkl/2 phosphorylation. BMC Cancer 2010; 10: 383.
12. Dowdell KC, Pesnicak L, Hoffmann V, Steadman K, Remaley AT, Cohen JI, et al. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 2009; 37: 487-494.
13. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280: 125-133.
14. Dietz KC, Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 2010; 62: 11-17.
15. Kothari V, Joshi G, Nama S, Somasundaram K, Mulherkar R. HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model. Int J Cancer 2010; 126: 733-742.
16. Di Micco S, Terracciano S, Bruno I, Rodriquez M, Riccio R, Taddei M, et al. Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorg Med Chem 2008; 16: 8635-8642.
17. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 2010; 12: 328-340.
18. Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, et al. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 2011; 88:418-424.
19. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77: 1156-1164.
20. Flis S, Gnyszka A, Splawinski J. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. Biochem Biophys Res Commun 2009; 387: 336-341.
21. Roos WP, Jost E, Belohlavek C, Nagel G, Fritz G, Kaina B. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-beta and valproic acid. Cancer Res 2011;71:4150-4160.
22. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005; 114: 380-386. (Pubitemid 40279957)
23. Meador JA, Zhao M, Su Y, Narayan G, Geard CR, Balajee AS. Histone H2AX is a critical factor for cellular protection against DNA alkylating agents. Oncogene 2008; 27: 5662-5671.
24. Kobayashi J, Tauchi H, Chen B, Burma S, Tashiro S, Matsuura S, et al. Histone H2AX participates the DNA damage-induced ATM activation through interaction with NBS1. Biochem Biophys Res Commun 2009; 380: 752-757.